ArticleJournal of the American Pharmacists Association : JAPhA
Organizational preparedness for implementing an evidence-based multilevel intervention to improve the timeliness of lung cancer treatment.
Article in Journal of the American Pharmacists Association : JAPhA. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDelayed time to treatment is a key determinant of poor survival among patients with lung cancer. Factors affecting the timeliness of lung cancer treatment are multilevel in nature. Most interventions target only 1 level of influence. Existing evidence-based interventions that work in 1 setting may fail to work in a different setting owing to poor fit in the new setting or deviations from the original intervention. Our study evaluated the feasibility of adopting a Veterans Health Administration (VHA) evidence-based multilevel intervention (EBMLI) within an academic health system.
methodsThe VHA EBMLI is a multilevel lung cancer care coordination program previously used by the VHA targeting the individual, provider team, and organization levels. The intervention effectively reduced time to treatment for Veterans with lung cancer over 7 years with statistically significant individual-level reductions by approximately 50%. We conducted a survey of providers across 5 sites on the acceptability, appropriateness, and feasibility toward the EBMLI using the following validated scales: (1) acceptability of intervention measure (AIM) (score range 1-5), (2) intervention appropriateness measure (IAM) (1-5), (3) feasibility of intervention measure (FIM) (1-5), (4) implementation climate scale (ICS) (0-4), and (5) implementation leadership scale (ILS) (0-4).
resultsA total of 45 providers consented to participate in the survey, and 36 (mean age 46 ± 11 years) across 5 sites completed the survey. Most had MD or PhD degrees (46%), were physicians (42%), and had >10 years' health care experience (49%) with 20 ± 20 patients with lung cancer seen per week, of whom 60% of providers saw only adult patients. Mean scores on the scales were AIM (4.1 ± 0.8), IAM (4.0 ± 0.8), FIM (4.1 ± 0.8), ICS (2.7 ± 0.7), and ILS (3.2 ± 0.9).
conclusionAlthough the proposed EBMLI may be well received by providers and leadership, acknowledgment of contexts affecting organizational climate is needed to ensure the feasibility of the adaptation, implementation, and sustainability of the VHA EBMLI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.